Chihiro Horimai
Overview
Explore the profile of Chihiro Horimai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yoshida T, Yamashita M, Horimai C, Hayashi M
J Am Heart Assoc
. 2017 Nov;
6(11).
PMID: 29146611
Background: Hyperphosphatemia is a major factor promoting the formation of arterial medial calcification in chronic kidney disease (CKD). However, arterial medial calcification begins to occur during the early stages of...
2.
Yoshida T, Yamashita M, Horimai C, Hayashi M
J Biol Chem
. 2014 Aug;
289(38):26107-26118.
PMID: 25100730
Kruppel-like factor 4 (KLF4) plays an important role in vascular diseases, including atherosclerosis and vascular injury. Although KLF4 is expressed in the heart in addition to vascular cells, the role...
3.
Yoshida T, Yamashita M, Horimai C, Hayashi M
J Am Heart Assoc
. 2014 Jan;
3(1):e000622.
PMID: 24470523
Background: Krüppel-like factor 4 (Klf4) is involved in a variety of cellular functions by activating or repressing the transcription of multiple genes. Results of previous studies showed that tamoxifen-inducible global...
4.
Yoshida T, Yamashita M, Horimai C, Hayashi M
J Vasc Res
. 2013 Nov;
50(6):512-20.
PMID: 24216515
High phosphate-induced phenotypic switching of smooth muscle cells (SMCs) into osteogenic cells is critical for the formation of arterial medial calcification in chronic kidney disease. Because vascular calcification is also...
5.
Yoshida T, Yamashita M, Horimai C, Hayashi M
J Am Heart Assoc
. 2013 May;
2(3):e000230.
PMID: 23702880
Background: Vascular proliferative diseases such as atherosclerosis are inflammatory disorders involving multiple cell types including macrophages, lymphocytes, endothelial cells, and smooth muscle cells (SMCs). Although activation of the nuclear factor-κB...
6.
Kawai T, Takei I, Shimada A, Hirata T, Tanaka K, Saisho Y, et al.
Clin Drug Investig
. 2010 Dec;
31(4):237-45.
PMID: 21184621
Background And Objective: Angiotensin II type 1 (AT1) receptor antagonists (angiotensin receptor blockers [ARBs]) are widely used for the treatment of not only hypertension but also cardiac dysfunction. B-type natriuretic...
7.
Fukuda S, Horimai C, Harada K, Wakamatsu T, Fukasawa H, Muto S, et al.
Clin Exp Nephrol
. 2010 Nov;
15(1):41-9.
PMID: 21072674
Background: Aldosterone induces inflammation and fibrosis in the kidney, while nuclear factor κB (NFκB) plays key roles in inflammation mediated by various cytokines. Here, we determined the roles of NFκB...
8.
Saisho Y, Hirose H, Horimai C, Miyashita K, Takei I, Umezawa K, et al.
Endocr J
. 2008 Apr;
55(2):433-8.
PMID: 18385532
Aims: Recent studies suggest that nuclear factor-kappaB (NF-kappaB) activation has an important role in leading to beta cell dysfunction in both type 1 and type 2 diabetes. In this study...